Melsmon solution for subcutaneous injection 2ml ampoules, 10pcs

Composition

Composition of 1 ampoule: Active ingredient: human placenta hydrolysate* – 100 mg; additional components: benzyl alcohol (preservative) – 30 mg, sodium hydroxide – up to pH 6,8-7, water for injection-up to 2 ml

Pharmacological action

The principle of action of Melsmon is not fully understood, but it is reliably established that the human placenta hydrolysate contains biologically active substances that have an antioxidant effect, increase the activity of tissue and cellular respiration, positively affect the metabolic processes in cells, and stimulate tissue regeneration. Also, the drug reduces fatigue and activates the body’s self-regulation processes, which helps to increase the adaptive mechanisms of the female body during premenopause and postmenopause.

Indications

According to the instructions, Melsmon is prescribed as part of complex therapy for peri – and postmenopausal women to correct asthenic conditions accompanied by excessive reactivity and excitability, decreased performance and attention.

Use during pregnancy and lactation

Pregnancy and breast-feeding are contraindications to the use of Melsmon.

Recommendations for use

Melsmon is intended exclusively for subcutaneous use. Recommended dosage: 1 ampoule (2 ml) every other day (i. e. 3 ampoules per week). The course of therapy is 2 weeks. If the need arises, the doctor recommends a second course after 1-2 weeks of break.

Contraindications

Arterial hypertension; disorders of the endocrine glands; childhood; pregnancy and lactation; hypersensitivity to any component of Melsmon. The drug is recommended to be used with caution in the following cases: weakened condition of the patient; diabetes mellitus; progressive cardiovascular diseases; renal and/or liver failure; cholelithiasis.

Side effects

Local reactions in the area of use of the drug: feeling of warmth, redness, soreness; allergic reactions: chills, fever, urticaria, itching, rash, allergic dermatitis; other: nausea, pain in the breast. In case of any of the listed reactions or any other side effect, you should consult a doctor for advice.

Interaction

Melsmon can be used as part of a complex treatment with other drugs for the treatment of conditions characteristic of peri-and postmenopausal women. There are no data on other clinically significant interactions of this drug. However, in order to avoid the development of negative reactions, it is recommended to coordinate with the doctor the possibility of simultaneous use of a particular drug.

Overdose

No overdose cases were reported.

Special instructions

The drug does not contain biological stimulants such as enzymes, hormones, proteins, or growth factors. Completely cleansed of toxic substances, it is anti-allergenic and non-pyrogenic. Intravenous use of Melsmone is strictly prohibited! Peri-and postmenopausal women should have a medical checkup. The doctor determines the frequency individually, but examinations should be carried out at least once every six months. Influence on the ability to drive vehicles and complex mechanisms The components included in the preparation do not affect attention, the speed of mental and physical reactions, and, consequently, do not affect the ability to drive vehicles and work with complex mechanisms.

Form of production

Solution for subcutaneous use: clear or slightly opalescent, from light yellow to yellow with a brown tinge of color, has a specific smell

Storage conditions

Protected from light, temperature up to 25 °C. Keep out of reach of children.

Shelf

life is 2 years.

Active ingredient

Human placenta hydrolysate

Conditions of release from pharmacies

Prescription